Trial Profile
An open label,3 month study evaluating effect of Istradefylline on daytime sleepiness and sleep disturbances in patients with Parkinson's disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jul 2017
Price :
$35
*
At a glance
- Drugs Istradefylline (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 15 Jul 2017 New trial record
- 08 Jun 2017 Results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders